tirzepatide studies 2025 vs Semaglutide: NEJM Study Reveals Superior Weight Loss Tirzepatide vs. Semaglutide: Which Weight
Description
This is a completely independent evaluation by reviewers who do not work for UnitedHealthcare
SURMOUNT-2 SURMOUNT-2 is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study designed to evaluate the efficacy and safety of once-weekly Tirzepatide (10mg , 15mg) in adult patients with type 2 diabetes who are obese or overweight
Health markers like blood pressure, glucose, and lipids show substantial improvements
If you are participating in a clinical trial involving retatrutide, you should also contact your research team or trial investigator promptly if you experience any of the above symptoms, in accordance with the trial protocol
The other two are approved for managing type 2 diabetes, but are commonly prescribed off label for weight loss
As of 19 Mar 2025, we are not prescribing Tirzepatide to clients
